Key Concepts of Drug Delivery Systems

Why This Matters

Drug delivery systems sit at the intersection of engineering, biology, and chemistry. You're expected to know not just what these systems are, but why specific delivery routes exist, how release mechanisms work, and when engineers choose one approach over another. The underlying principles (bioavailability, pharmacokinetics, controlled release kinetics, and targeting specificity) appear repeatedly across exam questions and FRQs.

Don't just memorize that nanoparticles exist or that patches go on skin. Focus on the engineering trade-offs: Why does bypassing first-pass metabolism matter? What makes zero-order release kinetically superior for chronic conditions? How do surface modifications enable targeting? These conceptual connections will help you tackle compare-and-contrast questions and design-based problems where you must justify selecting one delivery system over another.

---

Route-Based Delivery: How Drugs Enter the Body

The administration route determines absorption rate, bioavailability, and patient compliance. Each route exploits different biological barriers and transport mechanisms to achieve therapeutic drug levels.

Oral Drug Delivery Systems

Oral delivery is the most common route because it's convenient, non-invasive, and supports patient compliance for chronic conditions. The major drawback is first-pass metabolism: after absorption in the GI tract, blood drains through the portal vein to the liver, where enzymes can extensively metabolize the drug before it ever reaches systemic circulation. This often significantly reduces bioavailability.

Effective dosing calculations must account for several variables: gastric pH (which affects drug ionization and solubility), food interactions (which can speed up or slow absorption), and GI motility (which determines how long the drug stays in contact with absorptive surfaces).

Transdermal Drug Delivery Systems

Transdermal systems (patches, gels) deliver drugs through the stratum corneum, the outermost skin barrier, for systemic effects. Because the drug enters the bloodstream directly through dermal capillaries, it bypasses first-pass metabolism entirely. This results in higher bioavailability for drugs that would otherwise be heavily degraded in the liver.

Many transdermal patches achieve zero-order release kinetics, maintaining steady plasma concentrations over time. This makes them ideal for drugs like nicotine, fentanyl, and hormones where consistent blood levels are critical.

Inhalation Drug Delivery Systems

The lungs offer a massive surface area ($\approx 70 \text{ m}^2$) with thin alveolar membranes and rich blood supply, enabling rapid systemic absorption. Particle size is critical for effective pulmonary delivery: an aerodynamic diameter of $1\text{–}5 \text{ μm}$ is required for deep lung (alveolar) deposition. Particles larger than $5 \text{ μm}$ tend to impact in the upper airways and get cleared by mucociliary transport.

The rapid onset of action makes inhalation essential for acute conditions like asthma attacks and COPD exacerbations, where seconds matter.

Injectable Drug Delivery Systems

Injectable delivery provides the highest bioavailability (100% for IV, since the drug enters the bloodstream directly) and bypasses all absorption barriers.

• IV for emergencies and precise dosing control
• IM for depot formulations that slowly release drug from the muscle tissue
• Subcutaneous for self-administered biologics like insulin

This route is essential for large molecules such as proteins, monoclonal antibodies, and peptides that would be degraded by GI enzymes if taken orally.

---

Controlled Release: Engineering Drug Kinetics

Controlled release systems manipulate when and how fast drugs are released, transforming pharmacokinetic profiles. The goal is matching release rate to therapeutic need, whether that's sustained levels for chronic disease or pulsatile delivery for circadian rhythms.

Controlled Release Drug Delivery Systems

These systems use predetermined release rates to reduce dosing frequency, sometimes from multiple daily doses down to once-daily or even weekly formulations. Three primary release mechanisms drive these systems:

1. Diffusion through a polymer matrix or across a rate-controlling membrane
2. Erosion/degradation of the carrier material, gradually exposing encapsulated drug
3. Osmotic pumping, where water influx drives drug out through an orifice

The gold standard is zero-order kinetics (constant release rate), which maintains drug levels within the therapeutic window. This avoids concentration peaks that cause toxicity and troughs that reduce efficacy.

Osmotic Drug Delivery Systems

Osmotic systems use osmotic pressure as the driving force for release. Water flows through a semipermeable membrane into the tablet core, building pressure that pushes drug solution out through a laser-drilled orifice at a controlled rate.

The key advantage is highly predictable kinetics independent of pH or GI conditions. The release rate is determined by membrane permeability and the osmotic gradient, not by the surrounding environment. OROS technology (Osmotic Release Oral System) exemplifies this approach in commercial products like extended-release methylphenidate (Concerta).

Implantable Drug Delivery Systems

Implantable systems are placed internally to provide months to years of continuous therapy without patient intervention. They're ideal for chronic conditions where strict adherence is critical: contraception (Nexplanon), glaucoma treatment, and hormone replacement.

Two main design options exist:

• Reservoir systems with a rate-controlling membrane surrounding a drug core
• Biodegradable matrix systems where the carrier itself degrades over time, eliminating the need for surgical removal

---

Nanoscale and Particulate Systems: Engineering at the Molecular Level

Nanoscale carriers address fundamental drug delivery challenges: poor solubility, rapid clearance, off-target toxicity, and inability to cross biological barriers. These systems leverage size-dependent phenomena and surface engineering to change how drugs behave in the body.

Nanoparticle-Based Drug Delivery Systems

Nanoparticles in the $1\text{–}1000 \text{ nm}$ range exhibit unique biodistribution properties. They're small enough to extravasate through leaky tumor vasculature, a phenomenon called the Enhanced Permeability and Retention (EPR) effect. Tumor blood vessels have gaps (fenestrations) that normal vasculature lacks, and tumors also have poor lymphatic drainage, so nanoparticles accumulate preferentially at tumor sites.

• Solubility enhancement through encapsulation allows delivery of hydrophobic drugs that would otherwise precipitate in blood
• Surface modification with PEG ("PEGylation") extends circulation time by creating a hydrophilic "stealth" layer that reduces opsonization (protein adsorption) and subsequent immune clearance

Liposomal Drug Delivery Systems

Liposomes are lipid bilayer vesicles that mimic cell membranes. Their structure makes them naturally biocompatible and uniquely versatile: hydrophilic drugs can be encapsulated in the aqueous core, while hydrophobic drugs partition into the lipid bilayer.

Reduced systemic toxicity is a major clinical benefit. Doxil (liposomal doxorubicin) keeps the cytotoxic drug sequestered inside liposomes until it reaches tumor tissue, dramatically reducing the cardiotoxicity associated with free doxorubicin.

Targeting strategies include:

• Passive accumulation via the EPR effect
• Active targeting through surface-conjugated antibodies or ligands that bind receptors overexpressed on diseased cells

Hydrogel-Based Drug Delivery Systems

Hydrogels are three-dimensional polymer networks that swell in water while maintaining structural integrity, sometimes holding $>90\%$ water content. This high water content makes them highly biocompatible with surrounding tissues.

Stimuli-responsive "smart" hydrogels release drugs in response to environmental triggers: pH changes (useful in the GI tract or tumor microenvironment), temperature shifts, or the presence of specific enzymes. Localized delivery applications include wound healing, tissue engineering scaffolds, and injectable depots that gel in situ after injection.

---

Targeted Delivery: Precision Medicine Engineering

Targeted systems aim to concentrate drugs at disease sites while minimizing systemic exposure. The engineering challenge is achieving selectivity: getting drugs where they're needed while avoiding where they're not.

Targeted Drug Delivery Systems

Site-specific accumulation reduces the required dose and minimizes off-target side effects. This is especially critical for cytotoxic chemotherapy agents, where systemic exposure causes severe toxicity in healthy tissues.

Two fundamental targeting strategies exist:

• Passive targeting exploits pathophysiology without active recognition. The EPR effect in tumors and inflammation-increased vascular permeability are the two most common examples. No special surface chemistry is needed; size and circulation time do the work.
• Active targeting uses ligands, antibodies, or aptamers conjugated to carrier surfaces. These molecules bind receptors that are overexpressed on diseased cells (e.g., folate receptors on many cancer cells), increasing selective uptake.

Gene Delivery Systems

Nucleic acid therapeutics (DNA, mRNA, siRNA) require delivery vehicles because naked genetic material cannot cross cell membranes and is rapidly degraded by nucleases in the bloodstream.

• Viral vectors (AAV, lentivirus) offer high transfection efficiency and, in some cases, stable long-term expression. The trade-offs are immunogenicity (the body mounts an immune response against the viral capsid) and the risk of insertional mutagenesis (random genome integration disrupting host genes).
• Non-viral vectors (lipid nanoparticles, polymeric carriers) are safer and easier to manufacture at scale, but generally less efficient at delivering cargo into cells. The mRNA COVID-19 vaccines use LNP (lipid nanoparticle) technology, demonstrating the clinical viability of this approach.

---

Barrier-Crossing Technologies: Overcoming Biological Obstacles

Some delivery systems are engineered specifically to cross barriers that would otherwise block drug access: skin, mucosa, or cellular membranes. These technologies expand the range of drugs that can be delivered non-invasively.

Microneedle Drug Delivery Systems

Microneedles are micron-scale needles ($25\text{–}2000 \text{ μm}$) that penetrate the stratum corneum without reaching deeper pain-sensing nerve endings, enabling painless transdermal delivery.

Four main design variants exist:

1. Solid microneedles pretreat the skin by creating micropores, after which a topical formulation is applied
2. Coated microneedles carry drug on the needle surface that dissolves upon insertion
3. Dissolving microneedles are made of drug-loaded polymer that breaks down in the skin
4. Hollow microneedles function like miniature hypodermic needles for liquid injection

A notable advantage is vaccine delivery: microneedles target antigen-presenting cells (like Langerhans cells) in the dermis, potentially improving immune response compared to standard intramuscular injection.

Mucoadhesive Drug Delivery Systems

These systems adhere to mucosal surfaces (buccal, nasal, ocular, vaginal), extending residence time at absorption sites. Longer contact time means more drug gets absorbed.

Polymer selection determines adhesion strength. Common mucoadhesive polymers include chitosan, carbomers, and cellulose derivatives, which bind to mucus glycoproteins through hydrogen bonding and chain entanglement. The enhanced contact and permeation across mucosal epithelium improves bioavailability for drugs with poor oral absorption.

Microfluidic Drug Delivery Systems

Lab-on-a-chip technology enables precise control of fluid flow at microliter to nanoliter scales. The most clinically relevant application is closed-loop delivery systems that combine real-time monitoring with feedback-controlled drug release. Insulin pumps paired with continuous glucose monitors are the best current example.

Personalized medicine applications include point-of-care diagnostics integrated with on-demand drug release, where the device both detects a biomarker and responds with appropriate therapy.

---

Quick Reference Table

---

Self-Check Questions

1. Which two delivery systems both bypass first-pass metabolism but differ in their invasiveness and duration of action? Explain the engineering trade-offs between them.

2. A drug has poor aqueous solubility and causes severe systemic side effects. Which delivery system category would best address both problems, and what specific mechanisms would you employ?

3. Compare and contrast liposomal and polymeric nanoparticle delivery systems. Under what therapeutic circumstances would you choose one over the other?

4. An FRQ describes a patient requiring constant plasma drug levels for a chronic condition but with poor medication adherence. Rank three delivery system options and justify your top choice based on release kinetics and patient factors.

5. What distinguishes passive targeting from active targeting in nanomedicine? Identify one delivery system that can employ both strategies simultaneously and explain how.